Evaluation of the biological response to clopidogrel in patients with ischemic stroke

• Conditions: Ischemic stroke; MedDRA version: 16.1Level: LLTClassification code 10023027Term: Ischaemic stroke NOSSystem Organ Class: 100000004852; Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

• Registration Number: EUCTR2013-000313-20-FR
• Lead Sponsor: CHU de Saint-Etienne

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-04-08
• Last Update Posted: 11 January 2016

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

- Consent signed
- Patient over 18 years old
- Patients with non-cardioembolic AIC requiring initiation of treatment with clopidogrel as usual indications
- normal standard biological tests
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 30
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 50

Exclusion Criteria

- Need to continue aspirin therapy
- Patients with a recurrence of clopidogrel AIC
- Patient already tacking clopidogrel
- Drugs interfering with the adrenergic system alpha blockers, beta blockers, alpha 2 receptor agonists (alpha-methyldopa) and alpha2 receptor inhibitors (Mianserin, Mirtazapine, yohimbine)
- Contra indication of clopidogrel and / or any of its excipients

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified